Biogen (NASDAQ:BIIB) Shares Gap Down – Should You Sell?

Biogen Inc. (NASDAQ:BIIB) gapped down before the market opened on Tuesday . The stock had previously closed at $187.57, but opened at $179.46. Biogen shares last traded at $179.6680, with a volume of 410,474 shares.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose SPINRAZA regimen, broadening Biogen’s commercial opportunity in spinal muscular atrophy and supporting longer‑term rare‑disease revenue. This approval reinforces Biogen’s existing franchise and was cited as a near‑term positive driver for the stock. FDA SPINRAZA Approval
• Neutral Sentiment: Analysts largely kept Hold/neutral ratings and existing price targets after the Spinraza approval and incremental pipeline updates, signaling that the approval helps but does not meaningfully change consensus expectations. That keeps analyst guidance mixed for now. Analyst Reaction
• Negative Sentiment: Biogen agreed to acquire Apellis Pharmaceuticals for roughly $5.6B in cash ($41/ share plus contingent value payments), which unlocks empaveli and syfovre assets and accelerates an entry into nephrology — but the deal carries a material premium, near‑term cash outflow and integration risk. Investors appear concerned about the near‑term EPS/financial impact and capital deployment, which likely pressured BIIB despite the strategic rationale. Apellis Acquisition

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BIIB shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of Biogen in a research note on Monday, February 9th. Morgan Stanley set a $190.00 price objective on Biogen in a report on Sunday, February 8th. Wolfe Research set a $231.00 target price on Biogen in a research note on Monday, February 9th. Citigroup lifted their price target on Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Finally, HC Wainwright boosted their price target on Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Biogen currently has an average rating of “Hold” and a consensus target price of $205.31.

Biogen Trading Down 4.4%

The firm’s fifty day simple moving average is $185.83 and its 200 day simple moving average is $170.70. The stock has a market capitalization of $26.31 billion, a P/E ratio of 20.35, a price-to-earnings-growth ratio of 1.46 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same period in the prior year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Insider Transactions at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Biogen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock valued at $3,070,514,000 after acquiring an additional 157,857 shares in the last quarter. State Street Corp boosted its stake in Biogen by 1.0% during the second quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after acquiring an additional 71,897 shares in the last quarter. Geode Capital Management LLC grew its holdings in Biogen by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after purchasing an additional 130,618 shares during the period. Norges Bank acquired a new stake in Biogen in the fourth quarter worth $464,408,000. Finally, Invesco Ltd. increased its stake in Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after purchasing an additional 98,001 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.